Earlier this month, the FDA rejected Wyeth's Pristiq, an antidepressant that was being tested for menopausal symptoms, saying it wants additional clinical trials on the drug's heart and liver side effects.
That also is creating doubts about whether Pristiq will be approved as an antidepressant, a major concern since Wyeth's top seller, the antidepressant Effexor XR, is expected to go generic next year.